Presented for research literature review only Scannell C et al
The comprehensive treatment plan encompasses: consultations, assessment, lab monitoring, nutrition, sleep management, an exercise regimen, and stress/anxiety control
Pramlintide (approved 2005): three-amino-acid substitution enabling solubility, 2-3 daily dosing before meals, approximately 23% weight loss in T2D
Stringent cost and payer controls are a significant restraint in the GLP-1 drugs market due to the high prices associated with these therapies
Nakayama T, Mitsuno R, Azegami T, Sato Y, Hayashi K, Itoh H
Cardiovascular safety of albiglutide in the harmony programme: a meta-analysis